J. Bernhard

1.5k total citations
36 papers, 1.1k citations indexed

About

J. Bernhard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, J. Bernhard has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in J. Bernhard's work include Cancer survivorship and care (9 papers), Cancer Treatment and Pharmacology (8 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). J. Bernhard is often cited by papers focused on Cancer survivorship and care (9 papers), Cancer Treatment and Pharmacology (8 papers) and Childhood Cancer Survivors' Quality of Life (5 papers). J. Bernhard collaborates with scholars based in Switzerland, Germany and United States. J. Bernhard's co-authors include Christoph Hürny, Rudolf Maibach, Phyllis Butow, Richard Herrmann, Karin Ribi, U Laffer, Richard Brown, Maureen Wilson-Genderson, Ilona Juraskova and A Roth and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

J. Bernhard

35 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Bernhard Switzerland	18	510	451	148	134	123	36	1.1k
Heather Mackey United States	6	966 1.9×	345 0.8×	237 1.6×	91 0.7×	200 1.6×	9	1.3k
Melissa Accordino United States	18	445 0.9×	222 0.5×	112 0.8×	58 0.4×	94 0.8×	98	905
Nicole Burchardi Germany	16	497 1.0×	188 0.4×	164 1.1×	99 0.7×	143 1.2×	39	938
Belinda E. Kiely Australia	19	538 1.1×	228 0.5×	152 1.0×	169 1.3×	320 2.6×	81	1.0k
Jonathan D. Clapp United States	12	436 0.9×	613 1.4×	96 0.6×	40 0.3×	62 0.5×	16	962
Brittany A. Davidson United States	17	480 0.9×	111 0.2×	131 0.9×	86 0.6×	135 1.1×	90	1.2k
Inge R. Konings Netherlands	17	453 0.9×	220 0.5×	126 0.9×	58 0.4×	228 1.9×	42	1.0k
Jennifer Cullen United States	18	254 0.5×	741 1.6×	228 1.5×	43 0.3×	107 0.9×	82	1.3k
Nina N. Sanford United States	21	474 0.9×	402 0.9×	82 0.6×	77 0.6×	134 1.1×	113	1.2k
Prunella Blinman Australia	17	465 0.9×	271 0.6×	65 0.4×	129 1.0×	135 1.1×	53	787

Countries citing papers authored by J. Bernhard

Since Specialization

Citations

This map shows the geographic impact of J. Bernhard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Bernhard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Bernhard more than expected).

Fields of papers citing papers by J. Bernhard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Bernhard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Bernhard. The network helps show where J. Bernhard may publish in the future.

Co-authorship network of co-authors of J. Bernhard

This figure shows the co-authorship network connecting the top 25 collaborators of J. Bernhard. A scholar is included among the top collaborators of J. Bernhard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Bernhard. J. Bernhard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kienle, Dirk, Daniel Dietrich, Karin Ribi, et al.. (2018). Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of Geriatric Oncology. 10(2). 304–310. 17 indexed citations

Ribi, Karin, Weixiu Luo, J. Bernhard, et al.. (2015). Abstract S3-09: Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-po. Cancer Research. 75(9_Supplement). S3–9. 3 indexed citations

Ghadjar, Pirus, Philipp Gut, Matthias Gückenberger, et al.. (2015). Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10.. Journal of Clinical Oncology. 33(15_suppl). 5038–5038. 2 indexed citations

Bernhard, J., Weixiu Luo, Karin Ribi, et al.. (2014). Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).. Journal of Clinical Oncology. 32(15_suppl). 557–557. 10 indexed citations

Münger-Beyeler, Claudia, J. Bernhard, Kaspar Rufibach, R. Morant, & Hans‐Peter Schmid. (2007). Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience. Supportive Care in Cancer. 16(5). 461–467. 3 indexed citations

Weder, Walter, Rolf A. Stahel, J. Bernhard, et al.. (2007). Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Annals of Oncology. 18(7). 1196–1202. 239 indexed citations

Steinbach, Lynne S., et al.. (2005). Acromioclavicular joint cyst: nine cases of a pseudotumor of the shoulder. Skeletal Radiology. 34(5). 260–265. 39 indexed citations

Borner, Markus, J. Bernhard, Damien Dietrich, et al.. (2005). A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Annals of Oncology. 16(2). 282–288. 87 indexed citations

Holmberg, Stig B., Diana Crivellari, David Zahrieh, et al.. (2004). A randomized trial comparing axillary clearance versus no axillary clearance in older patients (≥ 60 years) with breast cancer: First results of International Breast Cancer Study Group Trial 10–93. Journal of Clinical Oncology. 22(14_suppl). 505–505. 3 indexed citations

10.

Pampallona, S., et al.. (2002). Socio-Demographic and Medical Characteristics of Advanced Cancer Patients Using Conventional or Complementary Medicine. Oncology Research and Treatment. 25(2). 165–170. 22 indexed citations

11.

Morant, R., S.‐F. Hsu Schmitz, J. Bernhard, et al.. (2002). Vinorelbine in androgen-independent metastatic prostatic carcinoma—a phase II study. European Journal of Cancer. 38(12). 1626–1632. 25 indexed citations

12.

Bernhard, J., A Lowy, Rudolf Maibach, & Christoph Hürny. (2001). Response shift in the perception of health for utility evaluation. European Journal of Cancer. 37(14). 1729–1735. 36 indexed citations

13.

Pampallona, S., et al.. (2000). Attitudes and Beliefs towards Disease and Treatment in Patients with Advanced Cancer Using Anthroposophical Medicine. Oncology Research and Treatment. 23(6). 558–563. 20 indexed citations

14.

Bernhard, J., Christoph Hürny, Rudolf Maibach, Richard Herrmann, & U Laffer. (1999). Quality of life as subjective experience: Reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Annals of Oncology. 10(7). 775–782. 103 indexed citations

15.

Bernhard, J., Monica Castiglione‐Gertsch, S.‐F. Hsu Schmitz, et al.. (1999). Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. European Journal of Cancer. 35(6). 913–920. 17 indexed citations

16.

Schmid, Hans‐Peter, Rudolf Maibach, J. Bernhard, et al.. (1997). A Phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Cancer. 79(9). 1703–1709. 23 indexed citations

17.

Bernhard, J., et al.. (1995). Quality-of-life assessment in cancer clinical trials: an intervention by itself?. Supportive Care in Cancer. 3(1). 66–71. 16 indexed citations

18.

Schwarz, R, et al.. (1994). Guidelines for the assessment of quality of life in oncology ?implementing adequate methods and their content. Journal of Cancer Research and Clinical Oncology. 120(11). 691–692. 6 indexed citations

19.

Hürny, Christoph, J. Bernhard, R Joss, et al.. (1992). Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer. Annals of Oncology. 3(10). 825–831. 37 indexed citations

20.

Butow, Phyllis, et al.. (1991). On the receiving end IV: Validation of quality of life indicators. Annals of Oncology. 2(8). 597–603. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact